HomeCompareEGRX vs PM

EGRX vs PM: Dividend Comparison 2026

EGRX yields 586.51% · PM yields 3.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EGRX wins by $215504.58M in total portfolio value
10 years
EGRX
EGRX
● Live price
586.51%
Share price
$0.34
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$215504.63M
Annual income
$161,378,417,110.69
Full EGRX calculator →
PM
Philip Morris International
● Live price
3.48%
Share price
$165.34
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,492.02
Full PM calculator →

Portfolio growth — EGRX vs PM

📍 EGRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEGRXPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EGRX + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EGRX pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EGRX
Annual income on $10K today (after 15% tax)
$49,853.37/yr
After 10yr DRIP, annual income (after tax)
$137,171,654,544.09/yr
PM
Annual income on $10K today (after 15% tax)
$296.12/yr
After 10yr DRIP, annual income (after tax)
$2,118.22/yr
At 15% tax rate, EGRX beats the other by $137,171,652,425.87/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EGRX + PM for your $10,000?

EGRX: 50%PM: 50%
100% PM50/50100% EGRX
Portfolio after 10yr
$107752.34M
Annual income
$80,689,209,801.36/yr
Blended yield
74.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

EGRX
Analyst Ratings
2
Buy
3
Hold
1
Sell
Consensus: Hold
Altman Z
1.7
Piotroski
4/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.5% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EGRX buys
0
PM buys
0
No recent congressional trades found for EGRX or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEGRXPM
Forward yield586.51%3.48%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$215504.63M$49.6K
Annual income after 10y$161,378,417,110.69$2,492.02
Total dividends collected$210965.27M$11.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy

Year-by-year: EGRX vs PM ($10,000, DRIP)

YearEGRX PortfolioEGRX Income/yrPM PortfolioPM Income/yrGap
1← crossover$69,351$58,651.03$11,648$408.29+$57.7KEGRX
2$454,347$380,141.02$13,589$495.90+$440.8KEGRX
3$2,813,681$2,327,530.38$15,877$603.21+$2.80MEGRX
4$16,481,619$13,470,979.69$18,580$734.88+$16.46MEGRX
5$91,381,654$73,746,322.23$21,781$896.75+$91.36MEGRX
6$479,912,426$382,134,055.57$25,578$1,096.12+$479.89MEGRX
7$2,389,083,497$1,875,577,201.52$30,092$1,342.17+$2389.05MEGRX
8$11,282,425,682$8,726,106,340.14$35,470$1,646.46+$11282.39MEGRX
9$50,585,242,215$38,513,046,735.24$41,892$2,023.58+$50585.20MEGRX
10$215,504,626,280$161,378,417,110.69$49,578$2,492.02+$215504.58MEGRX

EGRX vs PM: Complete Analysis 2026

EGRXStock

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Full EGRX Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this EGRX vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EGRX vs SCHDEGRX vs JEPIEGRX vs OEGRX vs KOEGRX vs MAINEGRX vs MOEGRX vs BTIEGRX vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.